Read by QxMD icon Read

Elena pentsova

Aki Morikawa, Lilly Jordan, Raquel Rozner, Sujata Patil, Adrienne Boire, Elena Pentsova, Andrew D Seidman
BACKGROUND: Disease presentation, prognostic factors, and treatment patterns for patients with breast cancer with leptomeningeal metastasis are not well characterized. In this study, we examined patient characteristics and prognostic factors for survival after a diagnosis of leptomeningeal metastasis. PATIENTS AND METHODS: Three hundred eighteen consecutive patients with breast cancer diagnosed with leptomeningeal metastasis from January 1998 to December 2013 at Memorial Sloan Kettering Cancer Center were identified...
July 25, 2016: Clinical Breast Cancer
Elena I Pentsova, Anne S Reiner, Katherine S Panageas, Lisa M DeAngelis
BACKGROUND: Despite optimal treatment for patients with anaplastic gliomas, median survival is 2 to 5 years, but some young adults survive longer. We sought to evaluate the functional and employment status of long-term survivors (5 years or more) diagnosed with anaplastic astrocytoma or non-1p/19q co-deleted anaplastic oligoastrocytoma. METHODS: We retrospectively identified patients with a diagnosis of anaplastic glioma at Memorial Sloan Kettering Cancer Center from 1999 to 2005...
June 2016: Neuro-oncology Practice
Elena I Pentsova, Ronak H Shah, Jiabin Tang, Adrienne Boire, Daoqi You, Samuel Briggs, Antonio Omuro, Xuling Lin, Martin Fleisher, Christian Grommes, Katherine S Panageas, Fanli Meng, S Duygu Selcuklu, Shahiba Ogilvie, Natalie Distefano, Larisa Shagabayeva, Marc Rosenblum, Lisa M DeAngelis, Agnes Viale, Ingo K Mellinghoff, Michael F Berger
PURPOSE: Cancer spread to the central nervous system (CNS) often is diagnosed late and is unresponsive to therapy. Mechanisms of tumor dissemination and evolution within the CNS are largely unknown because of limited access to tumor tissue. MATERIALS AND METHODS: We sequenced 341 cancer-associated genes in cell-free DNA from cerebrospinal fluid (CSF) obtained through routine lumbar puncture in 53 patients with suspected or known CNS involvement by cancer. RESULTS: We detected high-confidence somatic alterations in 63% (20 of 32) of patients with CNS metastases of solid tumors, 50% (six of 12) of patients with primary brain tumors, and 0% (zero of nine) of patients without CNS involvement by cancer...
July 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Ran Xu, Fumiko Shimizu, Koos Hovinga, Kathryn Beal, Sasan Karimi, Leif A Droms, Kyung K Peck, Philip Gutin, J Bryan Iorgulescu, Thomas J Kaley, Lisa M DeAngelis, Elena Pentsova, Craig Nolan, Christian Grommes, Timothy A Chan, Dylan Bobrow, Adilia Hormigo, Justin R Cross, Nian Wu, Naoko Takebe, Katherine Panageas, S Percy Ivy, Jeffrey G Supko, Viviane Tabar, Antonio M P Omuro
BACKGROUND: High grade gliomas are associated with a dismal prognosis. Notch inhibition via the gamma-secretase inhibitor RO2929097 has emerged as a potential therapeutic option based on modulation of the cancer-initiating cell (CIS) population and a presumed anti-angiogenic role. METHODS: In this phase 0/I trial, 21 patients with newly-diagnosed glioblastoma or anaplastic astrocytoma received RO4929097 combined with temozolomide and radiotherapy. In addition to establishing the maximum tolerated dose, the study design enabled exploratory studies evaluating tumor and brain drug penetration and neuro-imaging parameters...
May 6, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Macarena I de la Fuente, Robert J Young, Jennifer Rubel, Marc Rosenblum, Jamie Tisnado, Samuel Briggs, Julio Arevalo-Perez, Justin R Cross, Carl Campos, Kimberly Straley, Dongwei Zhu, Chuanhui Dong, Alissa Thomas, Antonio A Omuro, Craig P Nolan, Elena Pentsova, Thomas J Kaley, Jung H Oh, Ralph Noeske, Elizabeth Maher, Changho Choi, Philip H Gutin, Andrei I Holodny, Katharine Yen, Lisa M DeAngelis, Ingo K Mellinghoff, Sunitha B Thakur
BACKGROUND: The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but the sensitivity of this methodology and its clinical implications are unknown. METHODS: We developed an MR imaging protocol to integrate 2HG-MRS into routine clinical glioma imaging and examined its performance in 89 consecutive glioma patients...
February 2016: Neuro-oncology
Geraldine Faivre, Elena Pentsova, Alexis Demopoulos, Sophie Taillibert, Marc Rosenblum, Antonio Omuro
No abstract text is available yet for this article.
August 18, 2015: Neurology
Lakshmi Nayak, Katherine S Panageas, Anne S Reiner, Jason T Huse, Elena Pentsova, Stephanie G Braunthal, Lauren E Abrey, Lisa M DeAngelis, Andrew B Lassman
We previously reported results of a phase II non-comparative trial that randomized patients with glioblastoma following radiotherapy to one of two different temozolomide schedules, followed by 13-cis-retinoic acid (RA) maintenance. Here we report the results of an exploratory cohort of patients accrued with anaplastic astrocytic tumors. Patients with newly diagnosed anaplastic astrocytoma (AA) or anaplastic oligo-astrocytoma (AOA) were treated with concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), and six adjuvant 28-day cycles of either dose-dense (150 mg/m(2), days 1-7, 15-21) or metronomic (50 mg/m(2), days 1-28) temozolomide...
May 2015: Journal of Neuro-oncology
Lakshmi Nayak, Elena Pentsova, Tracy T Batchelor
PURPOSE OF REVIEW: This article provides a practical clinical approach to diagnose primary CNS lymphoma and recognize neurologic complications of lymphomas and leukemias. This includes current diagnostic and treatment recommendations for primary CNS lymphoma and complications related to hematologic malignancies. RECENT FINDINGS: Primary CNS lymphoma is an uncommon, aggressive non-Hodgkin lymphoma confined to the CNS in the absence of systemic disease. Diagnosis can be made by brain biopsy, CSF analysis, or vitreous fluid analysis...
April 2015: Continuum: Lifelong Learning in Neurology
Antonio Omuro, Denise D Correa, Lisa M DeAngelis, Craig H Moskowitz, Matthew J Matasar, Thomas J Kaley, Igor T Gavrilovic, Craig Nolan, Elena Pentsova, Christian C Grommes, Katherine S Panageas, Raymond E Baser, Geraldine Faivre, Lauren E Abrey, Craig S Sauter
High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to address chemoresistance and overcome the blood-brain barrier. In this single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy with rituximab, methotrexate (3.5 g/m(2)), procarbazine, and vincristine (R-MPV). Those with a complete or partial response proceeded with consolidation HDC with thiotepa, cyclophosphamide, and busulfan, followed by ASCT and no radiotherapy...
February 26, 2015: Blood
Antonio Omuro, Kathryn Beal, Philip Gutin, Sasan Karimi, Denise D Correa, Thomas J Kaley, Lisa M DeAngelis, Timothy A Chan, Igor T Gavrilovic, Craig Nolan, Adilia Hormigo, Andrew B Lassman, Ingo Mellinghoff, Christian Grommes, Anne S Reiner, Katherine S Panageas, Raymond E Baser, Viviane Tabar, Elena Pentsova, Juan Sanchez, Renata Barradas-Panchal, Jianan Zhang, Geraldine Faivre, Cameron W Brennan, Lauren E Abrey, Jason T Huse
PURPOSE: Bevacizumab is associated with decreased vascular permeability that allows for more aggressive radiotherapy schedules. We conducted a phase II trial in newly diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and bevacizumab. EXPERIMENTAL DESIGN: Patients with tumor volume ≤60 cc were treated with HFSRT (6 × 6 Gy to contrast enhancement and 6 × 4 Gy to FLAIR hyperintensity with dose painting) combined with concomitant/adjuvant temozolomide and bevacizumab at standard doses...
October 1, 2014: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Elena Pentsova, Lisa M Deangelis, Antonio Omuro
The prognosis of primary CNS lymphoma (PCNSL) recurring after methotrexate is poor (objective response rates [ORR] = 26-53 %; 1-year overall survival [OS] = 35-57 %). Salvage PCNSL chemotherapies have been based on the use of different agents to avoid cross-resistance; however, methotrexate is the most active agent in PCNSL, and methotrexate re-challenge may be an effective strategy for recurrent disease. We report our experience with methotrexate re-challenge in PCNSL. We reviewed 39 patients with histologically confirmed PCNSL who responded to methotrexate at initial diagnosis, experienced disease relapse and received methotrexate re-challenge...
March 2014: Journal of Neuro-oncology
Eli L Diamond, Vaios Hatzoglou, Bianca Santomasso, Marc Rosenblum, Elena Pentsova
No abstract text is available yet for this article.
January 2014: Neurohospitalist
Daniel E Spratt, Michael Folkert, Zachary S Zumsteg, Timothy A Chan, Kathryn Beal, Philip H Gutin, Elena Pentsova, Yoshiya Yamada
To determine the impact of delay between surgery and radiotherapy on overall survival (OS) in temozolomide treatmented patients with the incorporation of O6-methylguanine-DNA methyltransferase (MGMT). From 2000 to 2012, 345 consecutive glioblastoma patients were treated with surgery, radiotherapy, and temozolomide at our institution. A Cox-regression model was constructed using significant univariate parameters, known prognostic factors including MGMT, and the interval from surgery to radiotherapy (≤ 2, 2-5, and ≥ 6 weeks)...
January 2014: Journal of Neuro-oncology
Daniel Gorovets, Kasthuri Kannan, Ronglai Shen, Edward R Kastenhuber, Nasrin Islamdoust, Carl Campos, Elena Pentsova, Adriana Heguy, Suresh C Jhanwar, Ingo K Mellinghoff, Timothy A Chan, Jason T Huse
PURPOSE: Diffuse gliomas represent the most prevalent class of primary brain tumor. Despite significant recent advances in the understanding of glioblastoma [World Health Organization (WHO) IV], its most malignant subtype, lower grade (WHO II and III) glioma variants remain comparatively understudied, especially in light of their notable clinical heterogeneity. Accordingly, we sought to identify and characterize clinically relevant molecular subclasses of lower grade diffuse astrocytic gliomas...
May 1, 2012: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Elena Pentsova, Anli Liu, Marc Rosenblum, Eileen O'Reilly, Xi Chen, Adília Hormigo
Gemcitabine potential myotoxicity has been described in several cases of radiation recall and in patients treated with gemcitabine alone or in combination with other chemotherapy agents. We report two cases of gemcitabine related myositis identified at our institution, and perform a literature review of cases which meet the criteria for gemcitabine induced myositis associated to either radiation therapy or chemotherapy alone.
January 2012: Journal of Neuro-oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"